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Summary Cis-platinum causes profound gastrointestinal symptoms in patients and these may persist for
many days after drug administration. Gut mucosal toxicity may be a factor in the pathogenesis of such
prolonged nausea, vomiting and anorexia. The effects of cis-platinum on mouse ileal mucosal architecture,
villus epithelial cell influx and disaccharidase activity are described in comparison with dhe effects of two
platinum analogues, CBDCA and CHIP. In addition the effect of dexamethasone, a useful drug in the
palliation ofcis-platinum-induced emesis, in combination with cis-platinum is described.
Cis-platinum, CBDCA and CHIP cause profound reduction in crypt cell production rate (CCPR) and thus
villus epithelial cell influx within hours of administration leading to villus stunting and diminished function.
CBDCA showed the least profound effect with early rebound in CCPR by day 3. Cis-platinum and CHIP
were roughly equitoxic to ileal crypts with rebound in CCPR being delayed until day 7. Similarly, CBDCA
caused least reduction in disaccharidase activity with cis-platinum and CHIP being equitoxic. The addition of
dexamethasone had no protective effect on the effects of cis-platinum on murine ileal mucosa and mice given
the combination chronically had no weight gaii over 18 weeks, their weight paralleling those receiving cis-
platinum alone.
The platinate compounds have differing degrees of intestinal mucosal toxicity but no direct inference can be
drawn in respect to the clinical situation where CBDCA causes less gastrointestinal symptomatology than
CHIP but where both cause less than cis-platinum. Dexamethasone does not act by mucosal protection to
provide its useful effects in prolonged cis-platinum-induced gastrointestinal symptoms.
Since its introduction in the 1970s, cis-plIatindim has
become one of the most useful cytotoxic drugs in
clinical practice. However despite this the toxicity
associated with its use, viz. dose-limiting renal
toxicity, profound gastrointestinal symptomatology
and ototoxicity have been causes of great concern.
Methods of circumventing the renal toxicity
ensured its continued usage (Comis, 1980) but the
highly emetogenic nature of the compound is a
major drawback for patients receiving cancer
chemotherapy. Both central mechanisms (Borison &
McCarthy, 1983) and peripheral mechanisms
(Akwari, 1983) are thought to be involved in the
acute emesis associated with cis-platinum. The
pathogenesis of the prolonged gastrointestinal
symptoms, often up to 1 week after drug
administration, is uncertain and small-intestinal
mucosal toxicity may be involved. The development
of analogues of cis-platinum was aimed at
producing effective anti-tumour agents with less
toxicity than the original drug. Cis-diammine-1, 1-
cyclobutane dicarboxylate platinum (II) [CBDCA]
and cis-dichloro trans dihydroxy isopropylamine
(IV) [CHIP] are two such compounds which have
entered clinical trial (Calvert et al., 1982; Creaven
et al., 1983). Neither compound is associated with
significant renal toxicity and although it seems that
both compounds may cause emesis which is both
less acute and less prolonged than cis-platinum,
CHIP does cause more gastrointestinal sympto-
matology than CBDCA.
Considerable improvements in the control of cis-
platinum-induced emesis have been made with high
dose metoclopramide being the first advance in this
context (Gralla et al., 1981). Recently dexa-
methasone has been shown to enhance significantly
the efflcacy of high dose metoclopramide and
to reduce the duration of subsequent nausea
(Allan et al., 1984). The mechanism of action of
dexamethasone as an anti-emetic is not known.
These studies compare the effects of CHIP and
CBDCA with cis-platinum on the crypt cell
production, morphology and functional activity of
the mouse small intestine. In addition the effects of
a combination of dexamethasone and cis-platinum
on mouse small-intestinal mucosal toxicity are
addressed. It was hoped that the role of gastro-
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intestinal mucosal damage in the aetiology of cis-
platinum-induced emesis would be further
elucidated and that the mucosal effects of
dexamethasone in combination with cis-platinum
may be protective.
Materials and methods
All platinum compounds were dissolved in water
for injection i.p. into adult male CBA mice. In the
comparison of the platinum analogues maximally
tolerated doses of drugs were used, cis-platinum
10mgkg-1, CBDCA 100mgkg-1 and CHIP
40mgkg-1. Sections of ileum were taken on several
days (1,3, 5,7 and 10) after injection of the drugs,
in groups of four mice per drug per day. Colchicine
5mgkg- i.p. was administered to induce
metaphase arrest in the intestinal crypts (Tannock,
1969) and one mouse from each group was
sacrificed at 30min, 60min, 90min and 120min
following colchicine to allow later measuring of the
metaphase accumulation rate. A portion of ileum
(95th per cent of small-intestinal length) from each
mouse was placed in Clarke's fixative for 24h prior
to transfer to 75% ethanol for storage. A modified
microdissection technique was employed, utilising
Feulgen staining (Ferguson et al., 1977), to measure
individual villus and crypt heights, crypt to villus
number ratios and crypt cell production rate
(CCPR). The means of 20 measurements of villi
and crypt height from each treatment group were
calculated. CCPR was obtained from the rate of
accumulation of blocked metaphases, counted
visually and derived by linear regression based on a
mean count of ten crypts per animal. Villus
epithelial cell influx was derived from the product
of CCPR and crypt:villus ratio. To assess small
bowel function, disaccharidase activity was
measured (trehalase, sucrase). A portion ofjejunum
(35th per cent of small-intestinal length) from each
mouse was frozen and later analysed for trehalase
and sucrase activity by the method of Dahlqvist
(1964).
Two experiments were performed with a cis-
platinum/dexamethasone combination, looking
firstly at mucosal toxicity after a single exposure
(acute) to the drugs, the other (chronic) observing
effects after a sixth exposure at 18 weeks. In the
acute dexamethasone/cis-platinum experiment
groups of 6 male CBA mice were used and in the
chronic experiment groups of 3. Drugs were
administered to groups as follows (i) saline i.p.; (ii)
dexamethasone 4mgkg-1 s/c; (iii) cis-platinum
5mgkg-1 i.p.; (iv) cis-platinum 5mgkg-1 i.p. half
an hour after dexamethasone 4mgkg-1 s/c. The
cis-platinum dose was designed to ensure full
survival throughout the chronic experiment and the
dexamethasone dose was chosen to approximate to
potential human doses (Freireich, 1966). In the
chronic experiment drug injections were repeated at
3-weekly intervals for 6 courses and weights were
recorded weekly throughout. Metaphase arrest was
achieved in the intestinal crypts using colchicine
and portions of intestine taken and processed as
previously described. Ten measurements of villus
and crypt heights from each gut portion were made
in these experiments and the metaphase count on
each animal was a mean of 10 crypts as before. In
view of the multiple measurements used and the
variables involved, statistical analysis was by
analysis of variance and then comparison of
individual means by t-test.
Results
In the experiment comparing platinum analogues a
profound effect on CCPR was evident in all
treatment groups on day 1 post injections which
resulted in a marked reduction in villus epithelial
cell influx. The reduction in villus influx was most
marked in the CHIP treated group (Table I). Over
the succeeding days an apparent loss of crypts in
the CHIP and cis-platinum treated groups was
noted, reducing the crypt: villus ratio, although this
did not reach statistical significance. Therefore,
despite evidence of an increased CCPR on days 5-
10 in both these groups villus influx did not show a
compensatory over production until day 7. In the
CBDCA group over production of villus influx was
evident on day 3. Reductions of villus height were
observed at intervals following reduction in villus
influx. Thus a significant reduction in villus height
was seen between days 3-7 in the cis-platinum
group and significantly more profound effects were
noted in the CHIP group on days 1 and 3 (Figure
1). CBDCA caused a significant diminution of
villus height on day 3 with recovery by day 5
although a secondary reduction in villus height was
noted at day 10 which may correlate with an
apparent secondary dip in villus epithelial cell
influx on day 5 (Table I). The crypt heights give
some indication of proliferative activity in response
to the cytotoxic insult but are not discussed further.
Disaccharidase activity in jejunal mucosa was
used as a functional test of effects of the platinum
analogues. Both sucrase and trehalase activities
were measured with both showing a similar pattern.
The trehalase results are presented in Table II with
a statistical comparison. Cis-platinum caused a
significant reduction in trehalase activity on days 3,
5 and 7 compared with control and although CHIP
produced the most profound effects on trehalase
activity, recovering by day 10, these effects were
not significantly different from the cis-platinumEFFECT OF PLATINUM ANALOGUES ON SMALL-INTESTINAL MUCOSA
Table I (a) Villus influx (ileum) - comparison of
platinum analogues
Day post injection
Treatment group 1 3 5 7 10
Saline controls
CCPR (cells/h) 5.5 5.3 6.1 5.6 6.4
Crypt: villus ratio 4.9 4.9 5.0 4.1 4.8
Villus influx 27.2 26.0 31.1 23.7 31.4
Cis-platinum JOmgkg-
CCPR (cells/h) 2.8 4.1 6.8 10.8 9.4
Crypt: villus ratio 3.8 3.3 4.2 3.5 4.7
Villus influx 10.9 13.6 29.0 38.0 44.8
CBDCA (100mgkg-1)
CCPR (cells/h) 2.4 10.2 4.6 11.3 6.5
Crypt: villus ratio 4.5 5.0 5.0 4.8 4.9
Villus influx 11.0 51.5 23.7 54.8 32.1
CHIP (40mgkg 1)
CCPR (cells/h) 0.4 2.9 11.2 18.6 8.1
Crypt: villus ratio 3.2 3.0 2.2 2.5 3.3
Villus influx 1.3 8.9 25.6 47.1 27.1
Table I (b) Statistical comparisona of villus influx-
platinum analogues
Day post injection
Comparison 1 3 5 7 10
bcP vs. CBDCA NS <0.001 NS NS <0.025
bcP vs. CHIP <0.001 NS NS NS <0.05
CBDCA vs. CHIP <0.005 <0.001 NS NS NS
ap values by analysis of variance (t test on mean
values). bcP=cis-platinum.
group. CBDCA again showed least effect and no
significant difference from control values was
present by day 5. A rather high value was obtained
in the cis-platinum group on day 10.
In the experiments with dexamethasone cis-
platinum 5mg/kg causes marked inhibition of
CCPR as seen 24 hours after injection but crypt
regeneration is evident by day 3 as demonstrated by
an increased CCPR and villus epithelial cell influx
(Table III). Consequent to the reduction in villus
influx the villus height is maximally diminished by
day 3 but recovers thereafter (Figure 2). At this
dose of cis-platinum no effect was seen on the crypt
to villus ratio and thus the changes in villus influx
were mainly dependent on CCPR. No significant
Villus height
E
3 5 7 10
Day
Figure 1 Comparison of effects of platinate com-
pounds on villus and crypt heights. Each bar is the
mean of 20 villi or crypts from 4 mice (cis-platinum
10mgkg-': CBDCA 100mgkg-1: CHIP 40mgkg-1).
Control(E]); CBDCA(E); cis-platinum (E); CHIP(E).
* Significant difference from saline control (P<0.005);
+ Significant difference from CP control (P< 0.05).
Table II Comparison of trehalase activitya following
platinum analogues
Day post injection
1 3 5 7 10
Control 15.5 13.9 13.9 13.7 16.5
Cis-platinum 15.9 6.4 6.8 9.3 23.9
CBDCA 9.2 10.2 11.2 12.2 17.2
CHIP 15.4 8.2 4.4 7.3 16.9
aActivity=pmol substrate min-'g-1 wet wt.
Difference significant, P<0.025 (analysis of variance):
Cis-platinum vs. Control Day 3,5,7, 10
Cis-platinum vs. CBDCA Day 1,3,5, 10
Cis-platinum vs. CHIP N.S.
CBDCA vs. Control Day 1,3
CBDCA vs. CHIP Day 1,5,7
CHIP vs. Control Day 3,5,7
kinetic or morphological change was noted in the
dexamethasone controls and when dexamethasone
was combined with cis-platinum it was clear that no
protective effect is afforded to the ileum with this
combination (Table III and Figure 2). Indeed the
mean villus height is significantly less (P<0.02) in
the combination treated group compared with the
cis-platinum group on days 5, 7 and 10 although no
significant differences were calculated in villus
influx.
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Table Ill Villus influx (ileum) - cis-platinum and
dexamethasone (single injections)
Daypost injection
Treatment group 1 3 5 7 10
Saline controls
CCPR (cells/h) 6.0 6.1 5.8 5.6 5.5
Crypt: villus ratio 4.9 4.9 5.6 5.0 4.9
Villus influx 30.1 30.8 33.1 28.5 27.3
Dexamethasone controls
CCPR (cells/h) 7.2 7.3 5.9 5.4 5.7
Crypt: villus ratio 4.6 5.2 4.9 4.8 5.1
Villus influx 34.1 38.8 29.4 26.2 29.3
Cis-platinum
CCPR (cells/h) 1.6 10.1 6.8 8.1 6.5
Crypt: villus ratio 4.2 4.4 4.3 5.2 4.7
Villus influx 7.0a 45.5a 30.0 42.6a 30.8b
Cis-platinum/dexamethasone
CCPR (cells/h) 1.9 8.4 8.6 6.9 8.1
Crypt: villus ratio 4.6 4.0 4.5 5.1 5.0
Villus influx 9.18 34.5 39.5 35.5 41.2ab
aSignificant difference from control values, P<0.05
(analysis of variance). bSignficant difference between
groups 3 and 4, P<0.05 (analysis ofvariance).
In the experiment involving chronic adminis-
tration of cis-platinum and dexamethasone the
pattern of response of the ileum to the cytotoxic
insult of cis-platinum was similar to that seen in the
acute situation (Table IV). However, the
combination of dexamethasone and cis-platinum in
chronic dosing when compared with the cis-
platinum group demonstrated a greater reduction in
villus influx on day 1 (P<0.05) and a slower
recovery on day 7 (P<0.05). The administration of
dexamethasone to control mice did not alter
significantly their weights over an 18 week period
compared with saline controls. Both the cis-
platinum receiving groups failed to gain weight and
differed significantly from the control groups
throughout the observation period (P<0.05
analysis of variance) but did not differ from each
other (Figure 3).
Discussion
The integrity of the intestinal mucosa is dependent
on the crypt cell production rate and the crypt:
E
1 Uj b IU
Day
Figure 2 Comparison of villus and crypt heights
following a cis-platinum/dexamethasone combination.
Each bar is the mean of 60 villi or crypts from 6 mice
(cis-platinum 5mgkg-: dexamethasone 4mgkg-l
[acute]). Saline control (Ea); dexamethasone control
(Q); cis-platinum (M); cis-platinum+dexamethasone
(f). *, difference between CP and CP/dex (P<0.02,
ANOVA).
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Figure 3 Weight changes following chronic inter-
mittent cis-platinum/dexamethasone dosing (cis-
platinum 5mgkg- q 3 weekly: dexamethasone
4mgkg- q 3 weekly). Saline control (0); dexa-
methasone controls (Ol); platinum (@-@);
platinum+dexamethasone (0--- *). Each point is
the mean of 12 mice.
villus ratio. The product of these, the epithelial cell
influx can be profoundly influenced by changes in
the crypt cell production rate and the number of
residual crypts. Cis-platinum causes a profound
reduction in CCPR, maximal between 12-24h
(unpublished data) with a period of compensatory
rebound production which timing is dependent on
the cis-platinum dose administered. At higher doses
IC 31-.
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Table IV Villus influx (ileum) - cis-platinum
dexamethasone (chronic dosing)
and
Day post injection
Treatment group 1 3 5 7
Saline controls
CCPR (cells/h) 5.8 5.7 5.6 6.3
Crypt: villus ratio 5.4 4.8 5.0 5.1
Villus influx 31.5 27.7 28.5 32.9
Dexamethasone controls
CCPR (cells/h) 6.2 5.6 5.7 7.1
Crypt: villus ratio 5.1 4.2 4.6 5.4
Villus influx 32.2 24.3 26.8 39.0
Cis-platinum
CCPR (cells/h) 1.7 14.6 7.9 8.4
Crypt: villus ratio 4.9 4.1 5.6 4.9
Villus influx 8.8a 60.7a 44.8a 41.6b
Cis-platinum/dexamethasone
CCPR (cells/h) 1.0 11.8 7.5 6.1
Crypt: villus ratio 4.1 4.0 4.6 4.9
Villus influx 4.3 47.5 35.11 30.7b
'Significant difference from control, P<0.05. bGroups 3
and 4 significantly different P<0.05 (analysis of variance).
of cis-platinum an additional, smaller effect on
villus influx is provided by the temporary ablation
of crypts, although this loss was not statistically
significant. Following these effects on villus influx
the villus height becomes stunted and mucosal
function, as measured here by disaccharidase
activity, is diminished. When cis-platinum
5mgkg-1 was administered in a chronic inter-
mittent fashion the pattern of mucosal toxicity and
recovery was similar to that seen in the acute
situation, suggesting that crypt tolerance to the
repeated cytotoxic insult ofcis-platinum is high.
When the platinum analogues are compared with
cis-platinum, CHIP appears to be at least as toxic if
not more toxic to the intestinal mucosa with
compensatory rebound in villus influx occurring
only by day 7. CBDCA was the least toxic and
recovery was much more rapid although a
secondary unexplained reduction of villus height
was noted on day 10. CHIP and cis-platinum
appeared to cause loss of crypts but because of the
small sample sizes this did not reach statistical
significance. CBDCA caused least depression of
disaccharidase activity with recovery by day 5,
whereas CHIP and cis-platinum caused prolonged
depression beyond 7 days. The isolated high
trehalase value for cis-platinum is unexplained but
was not observed in estimations of sucrase activity
(unpublished data). It is clear from early clinical
studies of CHIP and CBDCA that gastrointestinal
toxicity, both acute and chronic emesis and
diarrhoea, is less than that produced by the parent
compound with CBDCA the least offensive. In the
mouse, CBDCA produces the least mucosal toxicity
of the three compounds examined but as CHIP is
as toxic as cis-platinum in the above experiments
no clear inference can be drawn with respect to the
human situation. It is clear that cis-platinum and
CHIP produce effects on the intestinal mucosa
which last for many days after the cytotoxic insult
and in the case of the former, control values of
CCPR are reached only by day 12 (unpublished
data). The correlation of prolonged gastrointestinal
symptoms with intestinal mucosal toxicity in
patients receiving platinate compounds is unproven
and human intestinal biopsies, in patients receiving
these compounds, may help in solving this issue.
Where efficacy is established the use of these
platinum analogues will reduce the morbidity of
cancer chemotherapy but where cis-platinum
continues to be used then amelioration of
associated gastrointestinal symptoms may be
achieved by effective anti-emesis (Allan et al., 1984)
or potentially by antidoting cis-platinum intestinal
cytotoxicity (Allan et al., 1985).
The useful anti-emetic activity of dexamethasone
both in non-cis-platinum and cis-platinum containing
chemotherapy-induced vomiting (Cassileth et al.,
1983; Allan et al., 1984) is unexplained. The latter
study showed that dexamethasone could shorten
the prolonged nausea associated with cis-platinum
administration. The dexamethasone/cis-platinum
experiments addressed the question of whether
dexamethasone had some protective role on cis-
platinum-induced mucosal toxicity in the mouse.
Clearly dexamethasone does not act to prevent this
toxicity and indeed it may enhance cis-platinum
toxicity. Although it has been reported that
glucocorticoids can stimulate intestinal mucosal
proliferation (Eastwood et al., 1981) the balance of
evidence is probably to the contrary. Wright &
Alison (1984) argue from the literature that gluco-
corticoids cause a block in GI-s transition in the
cell cycle. The addition of dexamethasone does not
prevent the weight loss associated with cis-platinum
in chronic dosing in the mouse. In man
dexamethasone effectively reduces cis-platinum
associated gastrointestinal symptoms but it may
well exert its effects centrally both to control the
acute emesis and the subsequent prolonged nausea,
vomiting and anorexia resulting from cis-platinum.
Dexamethasone may act peripherally to enhance
appetite following cis-platinum but in the mouse360 S.G. ALLAN & J.F. SMYTH
does not protect against structural mucosal toxiciLty
and thus will probably not alter the digestive
and absorbtive impairment which may ensue.
The role of small-intestinal mucosal toxicity in
the pathogenesis of prolonged gastrointestinal
symptoms subsequent to the use of cis-platinum
remains uncertain. Platinum analogues produce
intestinal toxicity in the mouse with varying
intensity. No direct inference can be drawn in
regard to the degree ofmurine mucosal toxicity and
the degree of gastrointestinal toxicity induced by
platinate compounds in the clinical situation.
Dexamethasone does not protect the small-
intestinal mucosa from the effects ofcis-platinum.
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